Page 1

Exhibit 99.1 BrainStorm Cell Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEW YORK , Aug 14 , 2026 / PRNewswire / -- BrainStorm Cell Therapeutics Inc. ( OTCQB : BCLI ) , a leading developer of adult stem cell therapeutics for neurodegenerative diseases , today announced financial results for the second quarter ended June 30 , 2026 , and provided a corporate update . " We continue to advance and complete the preparations necessary to initiate the Phase 3b ENDURANCE study of NurOwn in ALS , supported by an FDA - agreed protocol under a Special Protocol Assessment , ” said Chaim Lebovits , President and Chief Executive Officer of BrainStorm . “ The recent appointment of Peter Pitts as Executive Chairman represents an important enhancement to our leadership . Peter is joining the Company in an active executive capacity and will help lead the regulatory , operational , partnership and capital - markets initiatives surrounding the NurOwn program . His experience as a former senior FDA official brings an additional level of regulatory insight and strategic perspective as we prepare to enter this next phase . ALS imposes an enormous burden on patients , families and caregivers , and we remain resolute in our commitment to the ALS community and to advancing what we believe will be a valuable new therapeutic option . " Recent Highlights NurOwn® ( MSC - NTF ) for ALS • Advancing readiness for the Phase 3b ENDURANCE trial of NurOwn . BrainStorm is completing the operational and regulatory work needed to open ENDURANCE for enrollment . The trial is planned to enroll about 200 patients with ALS in two 24 - week parts : a randomized , double - blind , placebo - controlled portion ( Part A ) , then an open - label extension in which all participants receive NurOwn ( Part B ) . The primary endpoint is change on the ALSFRS - R scale , and Part A results are intended to support a new BLA . ENDURANCE will be conducted under a Special Protocol Assessment with the FDA , the first ever granted for an ALS therapeutic candidate . For more information , refer to ClinicalTrials.gov NCT06973629 . Corporate and Leadership Appointed Peter J. Pitts as Executive Chairman . In July 2026 , BrainStorm named Peter J. Pitts , a former FDA Associate Commissioner and co - founder of the Center for Medicine in the Public Interest , as Executive Chairman and Chief Strategic Regulatory and Policy Officer . Mr. Pitts , who joined the Board in May 2026 , will lead the Company's daily operations , partnerships , investor engagement , and regulatory strategy , focused primarily on advancing the Phase 3b ENDURANCE trial . Professor Jacob Frenkel , in BrainStorm's leadership since 2007 and Board Chairman since 2020 , will transition to Senior Advisor . Completed private placements totaling $ 400,000 , priced at a premium to market . In May 2026 , BrainStorm entered into private placement agreements for gross proceeds of $ 400,000 . Together with the $ 2.0 million raised in February 2026 , capital raised in first- half 2026 totals approximately $ 2.4 million .